VirtualScopics Reports Second Quarter 2013 Results 14% Increase in Second Quarter 2013 Revenues PR Newswire ROCHESTER, N.Y., Aug. 13, 2013 ROCHESTER, N.Y., Aug. 13, 2013 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging, today announced revenues of $3,706,677 for the quarter ended June 30, 2013 compared to $3,335,861 for the quarter ended June 30, 2012. Net income for the three months ended June 30, 2013 was $134,286 compared to a net loss of $62,966 for the three months ended June 30, 2012. Year to date 2013 new project awards totaled $15.9 million as compared to $4.6 million during the same period in 2012, a 246% increase. Other second quarter ended June 30, 2013 results were: oGross profit of $1,770,083 compared to $1,343,937 in the second quarter of 2012. oGross margin of 48% compared to 40% in the second quarter of 2012. oOperating income of $131,371 compared to an operating loss of $166,694 in the second quarter of 2012. oAdjusted EBITDA of $333,445 compared to $72,973 for the second quarter of 2012. Jeff Markin, president and chief executive officer of VirtualScopics stated, "We are very pleased with our performance in the second quarter which exhibited a 14% growth in revenue, a rebound in gross margins to 48%, resulting in a significant improvement in our operating performance and cash generation as compared to the first quarter of 2013." He continued, "We are also pleased with the amount of new project awards that we have received so far in 2013. New project awards are up more than 240% versus the similar period last year, and exceed the amount of new awards received during the full year of 2012." He concluded, "We are especially encouraged that more than 40% of our new study awards in 2013 are through our alliance with PPD which visibly validates the significant client benefits offered by our joint clinical and imaging solution." "Aside from the second quarter 2013 growth in revenues, one of the strongest financial accomplishments during the quarter was our gross margin performance," stated Molly Henderson, chief business and financial officer of VirtualScopics. She added, "By reporting margins approaching 50% we gained greater confidence in the productivity of our enhanced Phase III analysis tools." She continued, "Additionally, we are pleased to return to a quarter of generating cash as reported in our positive Adjusted EBITDA." She concluded, "During the second quarter of 2013, a single accelerated project represented a significant portion of the quarterly revenues. We do not anticipate a project of this magnitude recurring in a similar condensed time period during the remainder of this year. As a result, we estimate that our full year 2013 revenues will range between $10.5 million and 11 million." Jeff Markin and Molly Henderson will provide a business update and discuss these results during the Annual Stockholders' Meeting today at 11:00 am ET at the Country Club of Rochester in Rochester, New York. For those not able to attend in person, the script of the meeting will be available on the U.S. Securities and Exchange Commission's website at www.sec.gov. Additionally, the Company's management will hold a question and answer call at 11:00 am ET on Wednesday, August 14, 2013, for stockholders not able to attend the Annual Meeting in person. Interested participants should call 877-407-8035 when calling within the United States or +1 201 689 8035 when calling internationally. The Company provides Adjusted EBITDA as a supplemental measure to Generally Accepted Accounting Principles ("GAAP") regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization as further adjusted to exclude stock-based compensation expense and the loss/gain on derivative liabilities (mark to market adjustment for warrants). This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company's method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP, however, with the adoption of Accounting Standards Codification ("ASC") 815-40 and the non-cash variable nature of stock-based compensation expense and their very substantial impact on the overall reported net income/loss, the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net income/(loss), below. About VirtualScopics, Inc. VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com. Forward-Looking Statements The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements. -Financial tables to follow- CONTACTS: Company Contact: Molly Henderson Chief Business and Financial Officer, Sr. Vice President 500 Linden Oaks Rochester, New York 14625 +1 585 249.6231 VirtualScopics, Inc. and Subsidiary Condensed Consolidated Statements of Operations (unaudited) For the Three Months Ended For the Six Months Ended June 30, June 30, 2013 2012 2013 2012 $ $ $ $ Revenues 3,098,316 5,829,438 6,391,974 3,546,607 Reimbursement revenues 160,070 237,545 409,826 646,045 Total revenues 3,706,677 3,335,861 6,239,264 7,038,019 Cost of revenues* 1,776,524 1,754,379 3,274,063 3,637,124 Cost of reimbursement 160,070 237,545 409,826 646,045 revenues Total cost of 1,936,594 1,991,924 3,683,889 4,283,169 services Gross profit 1,770,083 1,343,937 2,555,375 2,754,850 Operating expenses Research and 333,423 357,839 767,268 714,166 development Sales and marketing 427,373 311,393 781,982 642,465 General and 688,213 615,159 1,578,249 1,269,899 administrative Stock-based compensation 99,149 119,249 227,093 295,185 expense Depreciation and 90,554 106,991 186,867 218,610 amortization Total operating 1,638,712 1,510,631 3,541,459 3,140,325 expenses Operating income 131,371 (166,694) (986,084) (385,475) (loss) Other income (expense) Interest income 3,342 715 4,351 1,130 Other expense (9,510) (5,446) (10,881) (5,713) Unrealized loss on change in fair value of derivative 9,083 108,459 13,953 (286,453) liabilities Total other income 2,915 103,728 7,423 (291,036) (expense) Net income (loss) 134,286 (62,966) (978,661) (676,511) Preferred stock deemed - 1,806,919 - 1,806,919 dividend Preferred stock 42,000 41,333 84,000 53,333 dividends Net income (loss) $ $ $ $ attributable to common (1,911,218) (1,062,661) (2,536,763) stockholders 92,286 Basic and diluted $ $ $ $ earnings (loss) per share 0.00 (0.06) (0.04) (0.09) Weighted average number of common shares outstanding basic 29,799,523 29,706,074 29,799,523 29,538,381 diluted 34,671,384 29,706,074 29,799,523 29,538,381 * Cost of revenues includes non-cash stock-based compensation expense of $12,371 and $13,427 for the three months ended June 30, 2013 and 2012, respectively and $25,214 and $26,758 for the six months ended June 30, 2013 and 2012, respectively. VirtualScopics, Inc. and Subsidiary Condensed Consolidated Balance Sheets June 30, December 31, 2013 2012 Assets (unaudited) Current assets Cash $ 7,145,743 $ 8,523,807 Accounts receivable, net 2,968,997 1,762,507 Prepaid expenses and other current assets 311,685 437,698 Total current assets 10,426,425 10,724,012 Patents, net 1,396,844 1,470,436 Property and equipment, net 280,007 399,569 Other assets - 5,428 Total assets $ 12,103,276 $ 12,599,445 Liabilities and Stockholders' Equity Current liabilities Accounts payable and accrued expenses $ 746,042 $ 872,652 Accrued payroll 664,251 481,661 Unearned revenue 446,714 272,509 Dividends payable 209,333 125,333 Total current liabilities 2,066,340 1,752,155 Commitments and Contingencies Stockholders' Equity Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized; Series C-1 3,000 shares authorized; issued and outstanding, 3,000 shares at June 30, 3 3 2013 and December 31, 2012; liquidation preference $1,000 per share Series B 6,000 shares authorized; issued and outstanding, 600 at June 30, 2013 and 1 1 December 31, 2012; liquidation preference $1,000 per share Series A 8,400 shares authorized; issued and outstanding, 2,190 at June 30, 2013 and 2 2 December 31, 2012; liquidation preference $1,000 per share Series C-2 3,000 shares authorized; issued and outstanding, 0 shares at June 30, 2013 - - and December 31, 2012; liquidation preference $1,000 per share Common Stock, $0.001 par value; 85,000,000 shares authorized; issued 29,958,795 and 29,799,523 shares at June 30, 2013 and 29,800 29,800 December 31, 2012, respectively; outstanding, 29,799,523 shares at June 30, 2013 and December 31, 2012, respectively Additional paid-in capital 21,949,391 21,781,084 Accumulated deficit (11,942,261) (10,963,600) Total stockholders' equity 10,036,936 10,847,290 Total liabilities and stockholders' equity $ 12,103,276 $ 12,599,445 Three Months Ended Three Months Ended Adjusted EBITDA (non-GAAP June 30, 2013 June 30, 2012 measurement): (unaudited) (unaudited) Net income (loss) $ $ 134,286 (62,966) Interest income and other 6,168 4,731 expenses Depreciation and amortization 90,554 106,991 Stock-based compensation expense 111,520 132,676 Unrealized gain on change in fair (9,083) (108,459) value of derivative liabilities Adjusted EBITDA $ $ 333,445 72,973 Basic Adjusted EBITDA per $ $ common share, non-GAAP 0.01 0.00 Diluted Adjusted EBITDA per $ $ common share, non-GAAP 0.01 0.00 Six Months Ended Six Months Ended Adjusted EBITDA (non-GAAP June 30, 2013 June 30, 2012 measurement): (unaudited) (unaudited) Net loss $ $ (978,661) (676,511) Interest income and other 6,530 4,583 expenses Depreciation and amortization 186,867 218,610 Stock-based compensation expense 252,307 321,943 Unrealized (gain) loss on change in fair value of derivative (13,953) 286,453 liabilities Adjusted EBITDA $ $ (546,910) 155,078 Basic Adjusted EBITDA per $ $ common share, non-GAAP (0.02) 0.01 Diluted Adjusted EBITDA per $ $ common share, non-GAAP (0.02) 0.01 SOURCE VirtualScopics, Inc. Website: http://www.virtualscopics.com
VirtualScopics Reports Second Quarter 2013 Results
Press spacebar to pause and continue. Press esc to stop.